Immunai, a pioneering startup dedicated to constructing a foundational model of the human immune system, has announced its third significant…
Read More
Protuoso Biosciences Secures $9.5 Million Seed Funding to Pioneer Multifunctional Biologics for Complex Diseases
Protuoso Biosciences, a burgeoning US-based biotechnology company, has successfully closed a $9.5 million seed financing round, positioning itself to revolutionize…
Read More
Autobahn Therapeutics Secures FDA Fast Track Designation for Elunetirom in Bipolar Depression
Autobahn Therapeutics has announced a significant milestone in its development of elunetirom, a novel central nervous system (CNS)-directed thyroid hormone…
Read More
UK Secures Favipiravir Supply from Japan to Bolster Hantavirus Preparedness
The United Kingdom has received a crucial supply of the antiviral medication favipiravir from the Japanese government, a strategic move…
Read More
Kyowa Kirin Secures FDA Approval for Enhanced Crysvita Dosing Regimen for Adults with X-Linked Hypophosphatemia
Kyowa Kirin has announced a significant advancement in the treatment landscape for X-linked hypophosphatemia (XLH) in adult patients, following the…
Read More
Isomorphic Labs Secures $2.1 Billion in Series B Funding to Accelerate AI-Driven Drug Discovery and Development
AI drug design and development firm Isomorphic Labs has successfully closed a significant $2.1 billion Series B funding round, marking…
Read More
GSK Secures Promising Metabolic Oligonucleotide Therapy Rights from SiranBio in Up to $1 Billion Deal
In a significant move to bolster its pipeline and solidify its strategic focus on the complex challenges of obesity, global…
Read More
Citius Oncology Secures Up to $36.5 Million in Debt and Equity Financing to Fuel Lymphir Commercialization
Citius Oncology has successfully secured a significant financial infusion, totaling up to $36.5 million, through a strategic combination of debt…
Read More
Madrigal Pharmaceuticals Secures Global Rights to Arrowhead’s siRNA Asset for MASH, Paving Way for Combination Therapy Exploration
Madrigal Pharmaceuticals has significantly bolstered its pipeline for metabolic dysfunction-associated steatohepatitis (MASH) by acquiring the global rights to Arrowhead Pharmaceuticals’…
Read More
Arrowhead Pharmaceuticals Secures Australian TGA Approval for Redemplo, Offering Hope for Familial Chylomicronemia Syndrome Patients
The Australian Therapeutic Goods Administration (TGA) has granted approval for Arrowhead Pharmaceuticals’ Redemplo (plozasiran), a novel therapeutic agent designed to…
Read MoreYOU MAY HAVE MISSED
